tetano
Editor, Senior Moderator
J Control Release
. 2020 Oct 7;S0168-3659(20)30580-0.
doi: 10.1016/j.jconrel.2020.10.009. Online ahead of print.
Ivermectin: An award-winning drug with antiviral expectations against COVID-19
Fabio Rocha Formiga[SUP] 1 [/SUP], Roger Leblanc[SUP] 2 [/SUP], Juliana de Souza Rebou?as[SUP] 3 [/SUP], Leonardo Paiva Farias[SUP] 4 [/SUP], Ronaldo Nascimento de Oliveira[SUP] 5 [/SUP], Lindomar Pena[SUP] 6 [/SUP]
Affiliations
Abstract
Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
. 2020 Oct 7;S0168-3659(20)30580-0.
doi: 10.1016/j.jconrel.2020.10.009. Online ahead of print.
Ivermectin: An award-winning drug with antiviral expectations against COVID-19
Fabio Rocha Formiga[SUP] 1 [/SUP], Roger Leblanc[SUP] 2 [/SUP], Juliana de Souza Rebou?as[SUP] 3 [/SUP], Leonardo Paiva Farias[SUP] 4 [/SUP], Ronaldo Nascimento de Oliveira[SUP] 5 [/SUP], Lindomar Pena[SUP] 6 [/SUP]
Affiliations
- PMID: 33038449
- DOI: 10.1016/j.jconrel.2020.10.009
Abstract
Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.